In one another encouraging published outcome, prescribing the blinatumomab, a BiTE, alongside anti-CD22 CAR-T cell led to the complete eradication of tumor cells and patients’ prolonged life span who relapsed after anti-CD22 CAR-T cell monotherapy [107]. Here, CD22 is linked to neoplasm.